Intervention Protocol

You have free access to this content

Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis

  1. Nicolas Goossens1,*,
  2. Graziella Isgro2,
  3. Francesco Negro1

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010504


How to Cite

Goossens N, Isgro G, Negro F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010504. DOI: 10.1002/14651858.CD010504.

Author Information

  1. 1

    Geneva University Hospital, Gastroenterology & Hepatology, Geneva, Switzerland

  2. 2

    Royal Free Hospital, The Royal Free Sheila Sherlock Liver Centre and Department of Surgery, London, UK

*Nicolas Goossens, Gastroenterology & Hepatology, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, Geneva, 1211, Switzerland. nicolas.goossens@hcuge.ch.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

References

Additional references

  1. Additional references
  2. References to other published versions of this review
Begg 1994
Bellentani 2009
  • Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology 2009;8(Suppl 1):S4-8.
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
Brok 2009
  • Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
Browning 2004
Brunt 1999
  • Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American Journal of Gastroenterology 1999;94:2467-74.
    Direct Link:
Chavez 2010
CTU 2011
  • Copenhagen Trial Unit. TSA - Trial Sequential Analysis. http://ctu.dk/tsa/ (accessed 18 Februar 2013).
Day 1998
Demets 1987
Der Simonian 1986
Egger 2003
Glanville 2006
  • Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94:130-6.
Gluud 2006
Gluud 2013
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 1. Art. No.: LIVER.
Guyatt 2008
  • Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2008;336(7650):924-6.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hollis 1999
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Kjaergard 2001
Kleiner 2005
Knodell 1981
Lirussi 2007
  • Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD004996.pub3]
Lundh 2012
Mahady 2011
  • Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. Journal of Hepatology 2011;55(6):1383-90.
McCullough 2002
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
Nelson 2009
  • Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Journal of Clinical Gastroenterology 20009;43:990-4.
Neuschwander 2003
Orlando 2007
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Savovic 2012
  • Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savovic 2012a
  • Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. The Journal of the American Medical Association 1995;273:408-12.
Shyangdan 2011
  • Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technology Assessment 2011;15(38):1-110.
Stein 2009
Thorlund 2009
  • Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 18 February 2013).
Tilg 2010
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.

References to other published versions of this review

  1. Additional references
  2. References to other published versions of this review
Angelico 2006
  • Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2006. [DOI: 10.1002/14651858.CD005166]
Angelico 2007